Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.
Chen Z, Wang Y, He T, Li H, Ao L, Pan Q, Zhou Y, Zhu Q, Xiang D, Zhang G, Ling N, Chen M, Hu P, Peng M, Cai D, Zhang D, Ren H.
Chen Z, et al.
J Clin Transl Hepatol. 2024 Feb 28;12(2):162-171. doi: 10.14218/JCTH.2023.00049. Epub 2023 Sep 6.
J Clin Transl Hepatol. 2024.
PMID: 38343613
Free PMC article.
RESULTS: The overall AEs in AILD patients after primary and booster vaccination were 26.2% and 13.3%, respectively. The decrease of C3 level and increase of immunoglobulin light chain kappa and lambda levels were observed in AILD patients after primary vaccination, however …
RESULTS: The overall AEs in AILD patients after primary and booster vaccination were 26.2% and 13.3%, respectively. The decrease of C3 …